LID

LIDDS (Local Intra-Deep Drug System) is a Swedish biotechnology company specializing in the development of targeted drug delivery systems for oncology. The company's core technology, NanoZolid, is a proprietary platform that enables the controlled, long-term release of drugs directly into or near a tumor, minimizing systemic side effects while maximizing local efficacy. Its lead clinical program, Liproca Depot, is a Phase 2-stage treatment for localized prostate cancer that utilizes the NanoZolid technology to deliver anti-androgens. Beyond prostate cancer, LIDDS is exploring the application of its platform to other solid tumors and in combination with immunotherapy to enhance treatment outcomes.